Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    06-March-2001      
Issue 65 Next Update - 14:00 UTC 08:00 EST    07-March-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya New Combinations Of Psoriasis Therapies Offer Positive Results

News From The American Academy Of Dermatology's 2001 Annual Meeting

The number of treatment options available to those with psoriasis has nearly doubled in the past few years. And the number of options is continuing to increase as dermatologists study combinations of new therapies and previously available treatments. Some of these combinations are improving patients' quality of life as they prove to be more effective and offer longer periods of remission.

Speaking today at the American Academy of Dermatology's 2001 Annual Meeting in Washington, D.C., dermatologist Mark Lebwohl, MD, Professor and Chairman, Department of Dermatology, Mount Sinai School of Medicine, New York, talked about new treatments for psoriasis, including those still in development, as well as the possibility of mixing treatments for greater results.

"Psoriasis is chronic and unpredictable, but these new treatments and combinations offer a greater chance of remission with less side effects -- something that is very important to individuals with psoriasis who have to find a long-term treatment that best fits their lifestyle," said Dr. Lebwohl.

Psoriasis is a recurring, noncontagious skin disorder that is characterized by raised, thickened patches of red skin covered with silvery-white scales. Psoriasis can range in severity and affect any part of the body, including the nails and scalp. It is estimated that over 7 million Americans have psoriasis, with more than 150,000 new cases reported each year.

New Psoriasis Treatments

Clobetasol propionate, one of the most effective topical corticosteroids for the treatment of psoriasis, has recently been approved as a foam specifically for the treatment of scalp psoriasis. The foam penetrates the skin easily, enhancing the effectiveness of the treatment. "Clobetasol foam is easy to use, less messy than other topical formulations, and therefore readily accepted by patients for the treatment of scalp psoriasis as well as psoriasis at other body sites," said Dr. Lebwohl. Tacrolimus ointment has recently been approved for the treatment of atopic dermatitis and does show promise for the treatment of psoriasis on the face and other areas prone to sensitivity and side effects when treated with other topical agents. However, the treatment does not seem effective for the treatment of thick plaque psoriasis.

New Combinations of Treatment Options

Calcipotriene, a topical vitamin D synthetic that has been available for several years, has recently been shown to have positive interactions with other psoriasis treatments. In particular, calcipotriene enhances the response of psoriasis when used in conjunction with ultraviolet light therapy (UVB), a treatment involving exposing the skin to ultraviolet-B light. Calcipotriene also increases the effectiveness of PUVA, a treatment involving the use of a prescription medication called psoralen and exposure to ultraviolet-A light. These enhanced responses can lead to faster remission.

While calcipotriene is not compatible with topical therapies such as salicylic acid, ammonium lactate and some corticosteroids, it can be used with halobetasol propionate, a topical steroid. Studies have shown that when calcipotriene and halobetasol are applied one on top of another, twice daily, their combined effect is superior to either treatment alone.

Even more promising is this combination for long-term treatment. "A regiment of halobetasol ointment applied on the weekends and calcipotriene ointment applied on the weekdays is capable of maintaining remission in 76 percent of treated patients," said Dr. Lebwohl. "That's compared to the 40 percent of patients who used only corticosteroid on the weekends and were able to maintain remission."

Tazarotene, a retinoid made from Vitamin A, also has positive interactions with other psoriasis therapies. It is compatible when mixed with most topical corticosteroids, resulting in less irritation and greater efficacy. Short-contact tazarotene therapy, applying tazarotene for one to five minutes, results in the effective clearing of psoriasis with reduced irritation. However, tazarotene does increase the risk for redness and sunburn during UVB and PUVA treatments; consequently, ultraviolet doses should be lowered by approximately one-third when this treatment is added to a phototherapy regimen.

New Therapies Show Promise

Clinical trials are just beginning in the United States on topical calcitriol, a vitamin D synthetic. It has proven safe and effective for the treatment of psoriasis, but is being tested for its efficacy before and after phototherapy, since it blocks transmission of UVB, narrow-band UVB, and PUVA.

"New treatments for psoriasis are making the management of the disease easier for patients," said Dr. Lebwohl. "And the possibility of combined treatments offers even greater hope for those who struggle to find therapies to assist them with this chronic condition."


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.